Clinical Pharmacology of Cardiac Myosin Modulators in Functional Heart Performance

Abstract

Cardiac myosin modulators represent a novel class of pharmacologic agents designed to directly target myocardial contractility by modulating the activity of cardiac myosin, the essential motor protein of cardiac muscle contraction. These agents offer a mechanism-based approach to augment or reduce contractile force, with implications for the management of systolic heart failure and other cardiomyopathies. This review synthesizes current evidence on the pharmacodynamics, pharmacokinetics, clinical efficacy, safety, and practical considerations for the use of cardiac myosin modulators, emphasizing their impact on functional heart performance and integrating recent guideline recommendations for their clinical application.

Introduction

The management of heart failure, particularly heart failure with reduced ejection fraction (HFrEF), has evolved considerably with the advent of therapies targeting neurohormonal pathways. However, persistent morbidity and mortality necessitate new approaches that target the fundamental drivers of impaired myocardial contractility. Cardiac myosin modulators have emerged as a unique therapeutic strategy, acting directly on the sarcomeric machinery to optimize cardiac performance. This review aims to provide clinicians and healthcare professionals with a comprehensive understanding of the clinical pharmacology of these agents, their mechanistic underpinnings, and their role in contemporary heart failure management.

Epidemiology / Disease Burden

Heart failure is a global epidemic affecting over 64 million individuals worldwide, with an annual incidence that continues to rise due to aging populations and improved survival from acute cardiovascular events. HFrEF accounts for a substantial proportion of cases and is associated with significant morbidity, frequent hospitalizations, and a five-year mortality rate approaching 50%. Despite established guideline-directed medical therapy, outcomes remain suboptimal, highlighting the need for innovative therapies targeting myocardial mechanics.

Pathophysiology

Systolic heart failure is characterized by impaired contractility resulting from alterations in the interaction between actin and myosin filaments within the cardiomyocyte sarcomere. Traditional pharmacotherapies indirectly enhance contractility by modulating calcium handling or neurohormonal tone, which may increase myocardial oxygen consumption and arrhythmic risk. Cardiac myosin modulators, by contrast, act directly on the myosin motor protein to optimize cross-bridge cycling and force generation, thereby improving cardiac output without adversely affecting myocardial energetics or increasing intracellular calcium.

Risk Factors

The primary risk factors for developing HFrEF include coronary artery disease, hypertension, diabetes mellitus, valvular heart disease, and genetic predisposition. Patients with these risk factors are at increased risk for structural and functional cardiac remodeling, ultimately leading to diminished myocyte contractility and clinical heart failure. Identification of high-risk populations is essential for early intervention and optimal therapeutic targeting.

Clinical Features

Patients with reduced left ventricular systolic function commonly present with exertional dyspnea, fatigue, orthopnea, paroxysmal nocturnal dyspnea, and signs of volume overload such as peripheral edema. On examination, findings may include an S3 gallop, displaced apex beat, and evidence of pulmonary or systemic congestion. The clinical severity is frequently classified using the New York Heart Association (NYHA) functional classification.

Diagnosis

The diagnosis of HFrEF is based on clinical assessment, supported by objective evidence of reduced ejection fraction on echocardiography (typically <40%). Additional investigations include measurement of natriuretic peptides (BNP or NT-proBNP), electrocardiography, chest radiography, and cardiac MRI for detailed structural and functional assessment. Biomarkers of myocardial injury and stress further aid in risk stratification and therapeutic monitoring.

Treatment & Management

Conventional management of HFrEF includes neurohormonal antagonists such as ACE inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs), beta-blockers, mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 (SGLT2) inhibitors. These agents improve survival and reduce hospitalization by modulating maladaptive neurohormonal activation. Cardiac myosin modulators, notably omecamtiv mecarbil, have been developed as adjuncts to standard therapy, offering direct augmentation of contractile performance. Dosing regimens are tailored to optimize therapeutic benefit while monitoring for adverse effects such as myocardial ischemia or arrhythmias.

Recent Advances / Emerging Therapies

Omecamtiv mecarbil is the prototypical cardiac myosin activator, demonstrated in the GALACTIC-HF trial to improve clinical outcomes in HFrEF patients at high risk of adverse events. It selectively increases the duration of systolic ejection, enhancing cardiac output without increasing myocardial oxygen consumption or arrhythmic risk. Danicamtiv and other investigational agents represent additional candidates in this class, with ongoing trials evaluating their safety and efficacy in broader heart failure populations. The clinical use of myosin inhibitors, such as mavacamten, is also expanding, particularly in the management of hypertrophic cardiomyopathy, reflecting the mechanistic versatility of this pharmacologic approach.

Guideline Recommendations

Recent heart failure guidelines from the American College of Cardiology, American Heart Association, and European Society of Cardiology recognize the potential role of cardiac myosin modulators in selected patients with symptomatic HFrEF despite optimized guideline-directed medical therapy. These agents are recommended as add-on therapy in patients at high risk for disease progression, particularly those with persistent symptoms or frequent hospitalizations. Careful patient selection, monitoring for efficacy and adverse effects, and integration with existing pharmacotherapies are emphasized for optimal clinical outcomes.

Conclusion

Cardiac myosin modulators represent a significant advancement in the pharmacologic management of heart failure, offering a mechanistically distinct and clinically meaningful approach to improving myocardial contractility. Early clinical data support their efficacy in enhancing functional heart performance with an acceptable safety profile. Continued research is warranted to define their long-term benefits, optimal patient selection, and integration into multidisciplinary heart failure care pathways. As evidence and experience grow, cardiac myosin modulators are poised to become an integral component of comprehensive heart failure management strategies.